Conference Dates: 5-6th October, 2011
Venue: London, UK
The UK Coalition Government has recently initiated a significant healthcare reform which in reality, presents both major challenges and opportunities to payers, policy-makers and the pharmaceutical industry.
The main components that will affect the pharmaceutical industry include a shift in the role of N.I.C.E. from the gatekeeper of market access to making strong, yet non-binding recommendations regarding cost-effectiveness of treatments. Decisions will be decentralized and delegated to the local-level as “GP Consortia”, who are closer to the patient will be empowered to reimburse based on local need. Furthermore, the existing Pharmaceutical Pricing & reimbursement Scheme (PPRS) will expire and the move will be made to an ambitious value-based pricing model from 2014. For the NHS too, value-based pricing can help to encourage that future applications for reimbursement and premium prices will only be met if the therapy will treat real public health concerns for a rapidly ageing population, improve quality of life and keep patients out of expensive hospital treatments and the burden on health budgets.
Current patient-access (risk-sharing) models may no longer fit under the new decentralised healthcare system and pharmaceutical companies in the UK are restructuring commercial operations to adjust access schemes to new models and decision-making processes.
This event will not only describe current and upcoming healthcare reforms but will also clarify how market-access and reimbursement decisions might proceed and with what effects.
• Focus on the most influential European market, that is central to global pricing strategy and a traditional pioneer in health technology assessment.
• Evaluate how pricing and reimbursement will be affected under the on-going NHS reform.
• Hear policy makers’ and payers’ views, initiatives and incentives on how the system will work in practice.
• Learn how innovation will be measured and rewarded in the UK in the near future.
• Understand all stakeholders’ roles in the increasingly decentralised decision-making process in the new healthcare reform.
• Find out more about the value-based pricing initiatives and their affect on pricing, market access and competition.
• Network with key decision makers who are involved in designing and implementing this significant reform.
Who will benefit?
Pharmaceutical and Medical devices companies:
Vice-Presidents, Directors, Managers involved in:
Pricing & Reimbursement, Health Economics & Outcomes, Government & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Marketing, Therapy Area Heads, Market Access, Country Managers
Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Regional Heads
Independent Academics, Health Economists, Government Officials, Public & Private Healthcare Providers, Senior Doctors, &Patient Representatives.
To request the full agenda please follow the link:
For Booking Information contact:
Tel: +421 232 660 382
Fax: +421 2 3301 0331